NCT06867939View on ClinicalTrials.gov

A Study of Curcumin (Soloways ™) in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 5, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

February 2, 2025

Conditions
Inflamatory Bowel Disease
Interventions
DIETARY_SUPPLEMENT

liposomal curcumin

Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.

DIETARY_SUPPLEMENT

Liposomal Curcumin

Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.

Trial Locations (1)

Unknown

Center for New Medical Technologies, Novosibirsk

All Listed Sponsors
lead

S.LAB (SOLOWAYS)

OTHER

NCT06867939 - A Study of Curcumin (Soloways ™) in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Biotech Hunter | Biotech Hunter